Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05193318 · ClinicalTrials.gov registry record · Phase 2

KAP for Depression in Abstinent Opioid Users

A Phase 2 study, sponsored by Medical University of South Carolina.

Terminated
Registry status
Phase 2
Development phase
5
Enrollment target

NCT05193318 is a Phase 2 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05193318, a Phase 2 study, was terminated before completion, sponsored by Medical University of South Carolina.

TERMINATED
Registry status
Phase 2
Development phase
5 participants
Enrollment target

Study Summary

The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine through intramuscular injection along with psychotherapy weekly for 8 weeks. Participation for eligible subjects who decide to enroll (including post-medication follow-up visits) will last about 16 weeks or 4 months.

Interventions

  • DRUG Ketamine-assisted psychotherapy

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2022-01-13
Est. Completion 2023-03-20
Phase Phase 2

What the Registry Record Tells You About NCT05193318

The ClinicalTrials.gov registry entry for NCT05193318 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ketamine-assisted psychotherapy is the first listed.

NCT05193318 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05193318 about?

NCT05193318 is a clinical study titled "KAP for Depression in Abstinent Opioid Users". The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused opioids in at least 3 months. Participants will receive ketamine throu...

What is the current status of trial NCT05193318?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2022-01-13. Estimated completion is 2023-03-20.

What interventions are being tested in trial NCT05193318?

The interventions under investigation include: Ketamine-assisted psychotherapy (DRUG).

Who is sponsoring clinical trial NCT05193318?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.